Anterogen Overview
- Year Founded
-
2000

- Status
-
Public
- Employees
-
29

- Stock Symbol
-
065660

- Share Price
-
$14.78
- (As of Friday Closing)
Anterogen General Information
Description
Anterogen Co Ltd is a bio-venture company engaged in the research and development of cell therapy products and orphan drugs using adult stem cells. Its products include Cupistem injection, Queen cell, Remodulin injection, and TheraStem-Derma. The company also offers cell banking services and analysis services that include sample analysis for clinical studies.
Contact Information
Website
www.anterogen.comCorporate Office
- 345-30 Gasan-dong
- Geumcheon-gu
- Seoul, 08589
- South Korea
Corporate Office
- 345-30 Gasan-dong
- Geumcheon-gu
- Seoul, 08589
- South Korea
Anterogen Stock Performance
As of 20-Jun-2025, Anterogen’s stock price is $14.78. Its current market cap is $148M with 10M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$14.78 | $14.81 | $9.64 - $17.73 | $148M | 10M | 21.6K | -$0.18 |
Anterogen Financials Summary
As of 31-Mar-2025, Anterogen has a trailing 12-month revenue of $5.02M.
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
---|---|---|---|---|
EV | 98,397 | 97,878 | 99,166 | 82,350 |
Revenue | 5,020 | 5,081 | 4,972 | 5,101 |
EBITDA | (2,394) | (2,260) | (1,884) | (4,166) |
Net Income | (1,736) | (1,680) | (2,173) | (5,291) |
Total Assets | 65,361 | 78,806 | 115,957 | 98,291 |
Total Debt | 0 | 0 | 7,558 | 10,065 |
Anterogen Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Anterogen Patents
Anterogen Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
JP-2025507128-A | Method for producing stem cell culture medium with increased growth factor content using a double crosslinked hydrogel scaffold and composition obtained therefrom | Pending | 08-Mar-2022 | ||
US-20230167143-A1 | Prodrugs of l-bhdu and methods of treating viral infections | Active | 29-Oct-2021 | ||
US-11945833-B2 | Prodrugs of l-bhdu and methods of treating viral infections | Active | 29-Oct-2021 | ||
CA-3235899-A1 | Prodrugs of l-bhdu and methods of treating viral infections | Pending | 29-Oct-2021 | ||
EP-4423100-A1 | Prodrugs of l-bhdu and methods of treating viral infections | Pending | 29-Oct-2021 | C07F9/65586 |
Anterogen Signals
Anterogen Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Anterogen ESG
Risk Overview
Risk Rating
Updated May, 18, 2022
30.75 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,912
Rank
Percentile

Pharmaceuticals
Industry
of 965
Rank
Percentile

Biotechnology
Subindustry
of 443
Rank
Percentile

Anterogen FAQs
-
When was Anterogen founded?
Anterogen was founded in 2000.
-
Where is Anterogen headquartered?
Anterogen is headquartered in Seoul, South Korea.
-
What is the size of Anterogen?
Anterogen has 29 total employees.
-
What industry is Anterogen in?
Anterogen’s primary industry is Biotechnology.
-
Is Anterogen a private or public company?
Anterogen is a Public company.
-
What is Anterogen’s stock symbol?
The ticker symbol for Anterogen is 065660.
-
What is the current stock price of Anterogen?
As of 20-Jun-2025 the stock price of Anterogen is $14.78.
-
What is the current market cap of Anterogen?
The current market capitalization of Anterogen is $148M.
-
What is Anterogen’s current revenue?
The trailing twelve month revenue for Anterogen is $5.02M.
-
What is Anterogen’s annual earnings per share (EPS)?
Anterogen’s EPS for 12 months was -$0.18.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »